TY  - BOOK
AU  - Brown, Ryan P
AU  - Eldadah, Zayd A
AU  - Hwang, Elizabeth
AU  - Kmiecik, Susanna
AU  - Levin, Bonnie
AU  - Lundergan, Conor
AU  - McAlduff, Joel
AU  - Shapiro, Richard
AU  - Smith, D Max
AU  - Swain, Sandra M
TI  - Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings
SN  - 1752-8054
PY  - 2020///
KW  - *Ambulatory Care/sn [Statistics & Numerical Data]
KW  - *Perioperative Care/sn [Statistics & Numerical Data]
KW  - *Pharmacogenomic Testing/sn [Statistics & Numerical Data]
KW  - *Practice Patterns, Physicians'/sn [Statistics & Numerical Data]
KW  - *Precision Medicine/sn [Statistics & Numerical Data]
KW  - Aged
KW  - Ambulatory Care/st [Standards]
KW  - District of Columbia
KW  - Female
KW  - Humans
KW  - Male
KW  - Maryland
KW  - Middle Aged
KW  - Perioperative Care/st [Standards]
KW  - Pharmacogenomic Testing/st [Standards]
KW  - Pilot Projects
KW  - Practice Guidelines as Topic
KW  - Practice Patterns, Physicians'/st [Standards]
KW  - Precision Medicine/mt [Methods]
KW  - Precision Medicine/st [Standards]
KW  - Retrospective Studies
KW  - United States
KW  - United States Food and Drug Administration/st [Standards]
KW  - MedStar Health
KW  - MedStar Heart & Vascular Institute
KW  - MedStar Union Memorial Hospital
KW  - MedStar Washington Hospital Center
KW  - SiTEL
KW  - Anesthesiology
KW  - Associate Dean for Research Development
KW  - Chief Medical Information Officer
KW  - Pharmacogenomics
KW  - Journal Article
N2  - Most literature describing pharmacogenetic implementations are within academic medical centers and use single-gene tests. Our objective was to describe the results and lessons learned from a multisite pharmacogenetic pilot that utilized panel-based testing in academic and non-academic settings. This was a retrospective analysis of 667 patients from a pilot in four perioperative and five outpatient cardiology clinics. Recommendations related to 12 genes and 65 drugs were classified as actionable or not actionable. They were ascertained from Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and U.S. Food and Drug Administration (FDA) labeling. Patients displayed a high prevalence of actionable results (88%, 99%) and use of medications (28%, 46%) with FDA or CPIC recommendations, respectively. Sixteen percent of patients had an actionable result for a current medication per CPIC compared to 5% per FDA labeling. A systematic approach by a health system may be beneficial given the quantity and diversity of patients affected. Copyright (c) 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics
UR  - https://dx.doi.org/10.1111/cts.12748
ER  -